Cite
HARVARD Citation
Tannir, N. et al. (2022). Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. Journal for immunotherapy of cancer. 10 (4), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Tannir, N. et al. (2022). Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. Journal for immunotherapy of cancer. 10 (4), p. . [Online].